Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Immune Checkpoint Inhibitors (ICIs) & Merkel-cell carcinoma (MCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Concerning Immune Checkpoint Inhibitors (ICIs) & Merkel-cell carcinoma (MCC), Immune Checkpoint Inhibitors (ICIs) have emerged as the standard treatment for patients with advanced Merkel cell carcinoma (MCC) in the frontline setting. Introducing Immune Checkpoint Inhibitors (ICIs) earlier in the disease progression, such as in neo-adjuvant and adjuvant contexts, is expected to enhance patient outcomes even more. Due to the uncommon nature of this cancer, it is crucial to coordinate efforts to conduct large-scale trials and effectively determine the most optimal care strategies (1)

References:

(1) Marchand et al. 2020 Expert Review of Anticancer Therapy 20: 1093-1106

References (Sources)

Immunobiology of Merkel cell carcinoma
Samimi et al. 2020 Current Opinion in Oncology. 32(2): 114-121
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy
Marchand et al. 2020 Expert Review of Anticancer Therapy 20: 1093-1106
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!